Overview
CARE9’s Oncology Solutions represent our flagship vertical, delivering comprehensive cancer care infrastructure through the Indo-African Oncology Institute (IAOI) framework: 250 bed tertiary oncology hospitals equipped with Linear Accelerators, PET-CT, molecular diagnostics, and tele-oncology platforms.
In February 2026, CARE9 formalized a landmark joint venture with Ghana’s Defence Industries Holding Company Limited (DIHOC), the Ghana Armed Forces, and the Ghana Medical Trust Fund (GMTF) to build the first comprehensive cancer and multi-specialty healthcare facility in Ghana, bringing sovereign institutional backing and government healthcare financing together with CARE9’s clinical and supply chain execution.
Indo-African Oncology Institute (IAOI) Framework
Infrastructure Components
Radiation Oncology
- Linear Accelerators (LINACs) with IMRT/VMAT capabilities
- Brachytherapy units
- Radiopharmacy facilities
- Treatment planning systems
Medical Oncology
- Chemotherapy day-care centers (50+ chairs)
- Oncology ICUs
- Bone marrow transplant units
- Palliative care wards
Surgical Oncology
- Dedicated oncology operation theaters
- Minimally invasive surgery capabilities
- Reconstructive surgery units
- 24/7 emergency oncology services
Diagnostic & Laboratory
- PET-CT and advanced imaging
- Molecular oncology labs
- NGS (Next Generation Sequencing)
- Liquid biopsy capabilities
- Immunohistochemistry
Digital Integration
Tele-Oncology Platform
- Remote tumor board consultations
- Second opinion services
- International expert collaboration
- Patient follow-up and monitoring
Cancer Registry
- National cancer data collection
- Epidemiological research
- Treatment outcome tracking
- Policy planning support
Mobile Screening Units
- Community-based early detection
- Rural outreach programs
- Breast and cervical cancer screening
- Health education campaigns
Impact Metrics (Projected per Institute)
- 100,000+ Patients screened annually
- 10,000+ New cancer cases treated per year
- 30-40% Reduction in outbound medical travel
- 1000+ Direct jobs created
- 500+ Healthcare workers trained
- National Cancer registry establishment
Service Offerings
Clinical Services
- Multi-disciplinary tumor boards
- Precision oncology and genomic testing
- Clinical trial participation
- Survivorship programs
- Psycho-oncology support
Training & Capacity Building
- Oncology fellowship programs
- Nursing specialization in cancer care
- Radiotherapy technician certification
- Research methodology training
Research & Innovation
- Translational cancer research
- Real-world evidence generation
- Health economics studies
- Quality of life assessments
Financial Model
PPP/BOOT Structure
- Total Investment: $80-120M per 250-bed facility
- Implementation Timeline: 24-30 months
- Operational Phase: 20-30 years
- Transfer: To government post-concession
Capital Stack
- DFI debt (50-60%)
- Export credit agency finance (20-30%)
- Sponsor equity (15-20%)
- Government contribution (land, licensing)
Revenue Streams
- Government long-term agreements
- National health insurance schemes
- Corporate partnerships
- International patient services
- Training and certification programs
Ghana Flagship: CARE9 x DIHOC x GMTF Joint Venture
In February 2026, CARE9 formalized a landmark joint venture with Ghana’s Defence Industries Holding Company Limited (DIHOC), the Ghana Armed Forces (GAF), and the Ghana Medical Trust Fund (GMTF) to build a comprehensive cancer and multi-specialty healthcare facility. The Ghana Armed Forces presented detailed proposals for the oncology facility, and GMTF confirmed alignment on financing cancer treatment through MahamaCare once the facility is operational.
This JV combines sovereign institutional backing (DIHOC/GAF), government healthcare financing (GMTF/MahamaCare), and vertically integrated clinical and supply chain execution (CARE9).
Regional Expansion Plan
Phase 1: Ghana Flagship (Confirmed 2026)
- Ghana: Comprehensive cancer and multi-specialty facility (JV with DIHOC, GAF, GMTF)
- Zimbabwe (Harare): 250 bed facility
- Nigeria (Lagos): 300 bed comprehensive center
Phase 2: Hub Expansion
- Cote d’Ivoire, Senegal, Kenya
- Brazil (Sao Paulo), Colombia (Bogota)
- Eastern Europe expansion
Target
- 1,000+ Oncology beds operational
- 6+ Countries with IAOI facilities
- 500,000+ Patients served
- 30% Reduction in medical travel across regions
Quality & Accreditation
- JCI (Joint Commission International) accreditation pathway
- IAEA (International Atomic Energy Agency) certification
- CAP (College of American Pathologists) lab accreditation
- ASCO (American Society of Clinical Oncology) guidelines compliance
Partnerships
- International cancer centers for knowledge transfer
- Pharmaceutical companies for clinical trials
- Medical equipment manufacturers
- Global oncology societies
- Patient advocacy organizations